Werewolf Therapeutics, Inc.
HOWL
$0.63
-$0.03-4.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -58.59% | -6.68% | -35.82% | 2.49% | 120.25% |
| Gross Profit | 58.59% | 6.68% | -160.86% | -9.23% | -182.89% |
| SG&A Expenses | -40.28% | -11.31% | -7.64% | -3.60% | -29.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.72% | -8.16% | -12.74% | 0.49% | 40.69% |
| Operating Income | 53.72% | 8.16% | 7.48% | -4.83% | -56.98% |
| Income Before Tax | 58.92% | 1.82% | -4.25% | -11.71% | -69.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.92% | 1.82% | -4.25% | -11.71% | -69.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.92% | 1.82% | -4.25% | -11.71% | -69.96% |
| EBIT | 53.72% | 8.16% | 7.48% | -4.83% | -56.98% |
| EBITDA | 54.70% | 8.07% | 7.40% | -5.19% | -59.22% |
| EPS Basic | 62.26% | 6.32% | -0.88% | -3.67% | -39.76% |
| Normalized Basic EPS | 62.26% | 6.29% | -4.21% | -3.70% | -39.79% |
| EPS Diluted | 57.14% | 5.64% | 5.97% | -3.67% | -39.76% |
| Normalized Diluted EPS | 62.89% | 6.29% | -5.49% | -3.70% | -39.79% |
| Average Basic Shares Outstanding | 8.87% | 4.80% | 3.36% | 7.74% | 21.62% |
| Average Diluted Shares Outstanding | 10.65% | 4.80% | 2.13% | 7.74% | 21.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |